Conditions: Renal Insufficiency
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 25
Healthy volunteers: yes

Brief summary:
This study will investigate and compare pharmacokinetics of a single 50 mg dose of odanacatib administered to participants with impaired renal/kidney function to those of a healthy matched control group. The primary hypothesis is that plasma AUC0-∞ of odanacatib in participants with impaired renal function is similar to that in matched healthy participants following a single 50 mg oral dose.

Detailed description:

Arms:
arm 1: Single-dose administration of odanacatib 50 mg to participants with severe renal insufficiency. arm 2: Single-dose administration of odanacatib 50 mg to healthy matched control participants.

Interventions: intervention 1: MK-0822
Intervention descriptions: intervention 1: A single oral dose (50 mg tablet) of MK-0822 will be administered on Day 1 after an overnight fast.

Protocol document: